Skandinaviska Enskilda Banken (SEB)
RARE icon

Skandinaviska Enskilda Banken (SEB)’s Ultragenyx Pharmaceutical RARE Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-67,720
Closed -$2.46M – 865
2025
Q2 		$2.46M Buy
67,720
+35,185
+108% +$1.27M 0.01% 549
2025
Q1 		$1.18M Buy
+32,535
New +$1.35M 0.01% 621

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s RARE Position: Q3 2025 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2025, closing a stake of 67,720 shares — an estimated $2.46M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in RARE in Q1 2025 and held it in 2 quarters. The position peaked at $2.46M in Q2 2025. 303 funds tracked by Wall St. Rank hold RARE as of Q3 2025.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Ultragenyx Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 67,720 Ultragenyx Pharmaceutical shares in Q3 2025, an estimated $2.46M.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Ultragenyx Pharmaceutical in Q1 2025 and held it in 2 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s Ultragenyx Pharmaceutical position peaked at $2.46M in Q2 2025.
  • 303 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2025.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q3 2025, filed 7 Nov 2025.